The role of the gut microbiome and its metabolites in metabolic diseases

Abstract

It is well known that an unhealthy lifestyle is a major risk factor for metabolic diseases, while in recent years, accumulating evidence has demonstrated that the gut microbiome and its metabolites also play a crucial role in the onset and development of many metabolic diseases, including obesity, type 2 diabetes, nonalcoholic fatty liver disease, cardiovascular disease and so on. Numerous microorganisms dwell in the gastrointestinal tract, which is a key interface for energy acquisition and can metabolize dietary nutrients into many bioactive substances, thus acting as a link between the gut microbiome and its host. The gut microbiome is shaped by host genetics, immune responses and dietary factors. The metabolic and immune potential of the gut microbiome determines its significance in host health and diseases. Therefore, targeting the gut microbiome and relevant metabolic pathways would be effective therapeutic treatments for many metabolic diseases in the near future. This review will summarize information about the role of the gut microbiome in organism metabolism and the relationship between gut microbiome-derived metabolites and the pathogenesis of many metabolic diseases. Furthermore, recent advances in improving metabolic diseases by regulating the gut microbiome will be discussed.

Keywords

gut microbiome / metabolism / metabolite / immune regulation / metabolic diseases

References

[1] Albaugh VL, Banan B, Antoun J, Xiong Y, Guo Y, Ping J, Alikhan M, Clements BA, Abumrad NN, Flynn CR (2019) Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery. Gastroenterology 156:1041–1051.e1044

[2] Albenberg LG, Wu GD (2014) Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology 146:1564–1572

[3] Al-Lahham SH, Roelofsen H, Priebe M, Weening D, Dijkstra M, Hoek A, Rezaee F, Venema K, Vonk RJ (2010) Regulation of adipokine production in human adipose tissue by propionic acid. Eur J Clin Invest 40:401–407

[4] Aron-Wisnewsky J, Warmbrunn M, Nieuwdorp M, Clement K (2020) Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? Gastroenterology 158:1881

[5] Bain CC, Cerovic V (2020) Interactions of the microbiota with the mucosal immune system. Immunology 159:1–3

[6] Bauere PV, Duca FA, Waise TMZ, Rasmussen BA, Abraham MA, Dranse HJ, Puri A, O’Brien CA, Lam TKT (2018) Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway. Cell Metab 27:101–117

[7] Brandhorst S, Longo VD (2019) Dietary restrictions and nutrition in the prevention and treatment of cardiovascular disease. Circ Res 124:952–965

[8] Canfora EE, Meex RCR, Venema K, Blaak EE (2019) Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol 15:261–273

[9] Chang PV, Hao L, Offermanns S, Medzhitov R (2014) The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA 111:2247–2252

[10] Corpeleijn E, Saris WH, Blaak EE (2009) Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev 10:178–193

[11] Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28:1221–1227

[12] da Cabo R, Mattson MP (2019) Effects of intermittent fasting on health, aging, and disease. N Engl J Med 381:2541–2551

[13] Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP (2018) Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep 8:1466

[14] David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505:559–563

[15] de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285:2109–2113

[16] Di Francesco A, Di Germanio C, Bernier M, de Cabo R (2018) A time to fast. Science 362:770–775

[17] Duboc H, Taché Y, Hofmann AF (2014) The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis 46:302–312

[18] Eloe-Fadrosh EA, Brady A, Crabtree J, Drabek EF, Ma B, Mahurkar A, Ravel J, Haverkamp M, Fiorino AM, Botelho C (2015) Functional dynamics of the gut microbiome in elderly people during probiotic consumption. mBio 6:e00231

[19] Enck K, Banks S, Yadav H, Welker ME, Opara EC (2020) Development of a novel oral delivery vehicle for probiotics. Curr Pharm Des 26:3134

[20] Ferrario C, Taverniti V, Milani C, Fiore W, Laureati M, De Noni I, Stuknyte M, Chouaia B, Riso P, Guglielmetti S (2014) Modulation of fecal clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr 144:1787–1796

[21] Forslund K, Hidebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottri V, Pedersen KH (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528:262–266

[22] Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, Anastasovska J, Ghourab S, Hankir M, Zhang S (2014) The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 5:3611

[23] Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, Zhu QY, Zhang T, Lelanc M, Liu SH (2019) FXR regulates intestinal cancer stem cell proliferation. Cell 176:1098–1112

[24] Funabashi M, Grove TL, Wang M, Varma Y, McFadden ME, Brown LC, Guo C, Higginbottom S, Almo SC, Fischbach MA (2020) A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature 582:566–570

[25] Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD (2017) Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev 14:491–502

[26] Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R (2018) Current understanding of the human microbiome. Nat Med 24:392–400

[27] Grundy SM (2012) Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 59:635–643

[28] Gu Y, Wang X, Li J, Zhang Y, Zhong H, Liu R, Zhang D, Feng Q, Xie X, Hong J (2017) Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun 8:1785

[29] Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y, Tang L (2016) Association between polycystic ovary syndrome and gut microbiota. PLoS ONE 11:e0153196

[30] Guo CJ, Allen BM, Hiam KJ, Dodd D, Van Treuren W, Higginbottom S, Nagashima K, Fischer CR, Sonnenburg JL, Spitzer MH (2019) Depletion of microbiome-derived molecules in the host using Clostridium genetics. Science 366:1282

[31] Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L (2019) Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature 576:143–148

[32] Hatori M, Vollmers C, Zarrinpar A, DiTacchio L, Bushong EA, Gill S, Leblanc M, Chaix A, Joens M, Fitzpatrick JAJ (2012) Timerestricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab 15:848–860

[33] Heymsfield SB, Wadden TA (2017) Mechanisms, pathophysiology, and management of obesity. Engl J Med 376:254–266

[34] Huang FJ, Zheng XJ, Ma XH, Jiang RQ, Zhou WY, Zhou SP, Zhang YJ, Lei S, Wang SL, Kuang JL (2019) Theabrownin from Puerh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. Nat Commun 10:4971

[35] Huang ZR, Deng JC, Li QY, Cao YJ, Lin YC, Bai WD, Liu B, Rao PF, Ni L, Lv XC (2020) Protective Mechanism of Common Buckwheat (Fagopyrum esculentum Moench.) against nonalcoholic fatty liver disease associated with dyslipidemia in mice fed a high-fat and high-cholesterol diet. J Agric Food Chem 68:6530–6543

[36] Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A (2011) Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141:1773–1781

[37] Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D (2015) Role of the normal gut microbiota. World J Gastroenterol 21:8787–8803

[38] Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, Brocker CN, Desai D, Amin SG, Bisson WH (2015) Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 6:10166

[39] Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS (2010) Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 59:1899–1905

[40] Kelley ST, Skarra DV, Rivera AJ, Thackray VG (2016) The gut microbiome is altered in a letrozole-induced mouse model of polycystic ovary syndrome. PLoS ONE 11:e0146509

[41] Kim DM (2015) Gut microbiota-mediated drug-antibiotic interactions. Drug Metab Dispos 43:1581–1589

[42] Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403

[43] Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, Hallen A, Martens E, Bjorck I, Backhed F (2015) Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella. Cell Metab 22:971–982

[44] Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O (2016) Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med 8:52

[45] Larraufie P, Martin-Gallausiaux C, Lapaque N, Dore J, Gribble FM, Reimann F, Blottiere HM (2018) SCFAs strongly stimulate PYY production in human enteroendocrine cells. Sci Rep 8:74

[46] Larsson H, Lindgärde F, Berglund G, Ahrén B (2000) Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study. Diabetologia 43:1224–1228

[47] Laursen MF, Laursen RP, Larnkjær A, Michaelsen KF, Bahl MI, Licht TR (2017) Administration of two probiotic strains during early childhood does not affect the endogenous gut microbiota composition despite probiotic proliferation. BMC Microbiol. https://doi.org/10.1186/s12866-017-1090-7

[48] Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A (2013) Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62:1787–1794

[49] Levy M, Thaiss CA, Zeevi D, Dohnalova L, Zilberman-Schapira G, Mahdi JA, David E, Savidor A, Korem T, Herzig Y (2015) Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163:1428–1443

[50] Li GL, Xie C, Lu SY, Nichols RG, Tian Y, Li LC, Patel D, Ma YY, Brocker CN, Yan TT (2017) Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota. Cell Metab 26:672–685

[51] Li Z, Yi CX, Katiraei S, Kooijman S, Zhou E, Chung CK, Gao Y, van den Heuvel JK, Meijer OC, Berbee JFP (2018) Butyrate reduces appetite and activates brown adipose tissue via the gutbrain neural circuit. Gut 67:1269–1279

[52] Lim PS, Loke CF, Ho YW, Tan HY (2020) Cholesterol homeostasis associated with probiotic supplementation in vivo. J Appl Microbiol

[53] Lindheim L, Bashir M, Munzker J, Trummer C, Zachhuber V, Leber B, Horvath A, Pieber TR, Gorkiewicz G, Stadlbauer V (2017) Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study. PLoS ONE 12:e0168390

[54] Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, Shi J, Zhao S, Liu W, Wang X (2017a) Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 23:859–868

[55] Liu R, Zhang C, Shi Y, Zhang F, Li L, Wang X, Ling Y, Fu H, Dong W, Shen J (2017b) Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol 8:324

[56] Longo VD, Panda S (2016) Fasting, circadian rhythms, and timerestricted feeding in healthy lifespan. Cell Metab 23:1048–1059

[57] Louis P, Hold GL, Flint HJ (2014) The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12:661–672

[58] Manco M, Putignani L, Bottazzo GF (2010) Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31:817–844

[59] Mao K, Baptista AP, Tamoutounour S, Zhuang L, Bouladoux N, Martins AJ, Huang Y, Gerner MY, Belkaid Y, Germain RN (2018) Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. Nature 554:255–259

[60] Matsubara T, Li F, Gonzalez FJ (2013) FXR signaling in the enterohepatic system. Mol Cell Endocrinol 368:17–29

[61] Meslier V, Laiola M, Roager HM, De Filippis F, Roume H, Quinquis B, Giacco R, Mennella I, Ferracane R, Pons N (2020) Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. Gut 69:1258–1268

[62] Miyamoto J, Igarashi M, Watanabe K, Karaki SI, Mukouyama H, Kishino S, Li X, Ichimura A, Irie J, Sugimoto Y (2019) Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nat Commun 10:4007

[63] Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B, American Diabetes A (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753–759

[64] Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. The Lancet 370:685–697

[65] Perez-Munoz ME, Arrieta MC, Ramer-Tait AE, Walter J (2017) A critical assessment of the “sterile womb” and “in utero colonization” hypotheses: implications for research on the pioneer infant microbiome. Microbiome 5:48

[66] Pi Y, Mu C, Gao K, Liu Z, Peng Y, Zhu W (2020) Increasing the hindgut carbohydrate/protein ratio by cecal infusion of corn starch or casein hydrolysate drives gut microbiota-related bile acid metabolism to stimulate colonic barrier function. mSystems 5: e00176–20

[67] Popkin BM, Adair LS, Ng SW (2012) Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev 70:3–21

[68] Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC, Ghatei MA, Bloom SR, Frost G (2015) The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes (Lond) 39:424–429

[69] Qi X, Yun C, Sun L, Xia J, Wu Q,Wang Y, Wang L, Zhang Y, Liang X, Wang L (2019) Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med 25:1225–1233

[70] Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, Bodai Z, Belda-Ferre P, Tripathi A, Chung LK (2020) Global chemical effects of the microbiome include new bile-acid conjugations. Nature 579:123–129

[71] Ragsdale SW, Pierce E (2008) Acetogenesis and the Wood-Ljungdahl pathway of CO(2) fixation. Biochem Biophys Acta 1784:1873–1898

[72] Rao RK, Seth A, Sheth P (2004) Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 286:G881–G884

[73] Reilly SM, Saltiel AR (2017) Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol 13:633–643

[74] Rubio LA, Aranda-Olmedo I, Martín-Pedrosa M (2020) Inclusion of limited amounts of extruded legumes plus cereal mixes in normocaloric or obesogenic diets for rats: effects on lipid profile. Foods (Basel, Switzerland)9

[75] Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, Mujagic Z, Masclee AAM, Jonkers D, Oosting M (2019) Causal relationships among the gut microbiome, shortchain fatty acids and metabolic diseases. Nat Genet 51:600–605

[76] Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H (2005) Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence report/technology assessment (Summary), 1–11

[77] Schroeder BO, Backhed F (2016) Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 22:1079–1089

[78] Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, Bross C, Durelle J, Goyal NP, Hamilton G (2019) Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology 157:1109–1122

[79] Sender R, Fuchs S, Milo R (2016) Are we really vastly outnumbered? revisiting the ratio of bacterial to host cells in humans. Cell 164:337–340

[80] Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG (1999) Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 22:399–402

[81] Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, Geva-Zatorsky N, Jupp R, Mathis D, Benoist C (2020) Microbial bile acid metabolites modulate gut RORγ(+) regulatory Tcell homeostasis. Nature 577:410–415

[82] Sun J, Buys NJ (2016) Glucose- and glycaemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebo-controlled trials. Br J Nutr 115:1167–1177

[83] Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B (2018) Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med 24:1919–1929

[84] Sun L, Pang Y, Wang X, Wu Q, Liu H, Liu B, Liu G, Ye M, Kong W, Jiang C (2019) Ablation of gut microbiota alleviates obesityinduced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. Acta Pharm Sin B 9:702–710

[85] Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM (2018) Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab 27:1212–1221

[86] Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E (2011) Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci USA 108(Suppl 1):4523–4530

[87] Thingholm LB, Ruhlemann MC, Koch M, Fuqua B, Laucke G, Boehm R, Bang C, Franzosa EA, Hubenthal M, Rahnavard A (2019) Obese Individuals with and without Type 2 diabetes show different gut microbial functional capacity and composition. Cell Host Microbe 26(252–264):e210

[88] Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM (2012) Shortchain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:364–371

[89] Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J (2015) Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun 6:7629

[90] Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350

[91] Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031

[92] Turnbaugh PJ, Backhed F, Fulton L, Gordon JI (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3:213–223

[93] Usami M, Kishimoto K, Ohata A, Miyoshi M, Aoyama M, Fueda Y, Kotani J (2008) Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res 28:321–328

[94] Vendrame F, Gottlieb PA (2004) Prediabetes: prediction and prevention trials. Endocrinol Metab Clin N Am 33(75–92):ix

[95] Vernocchi P, Del Chierico F, Putignani L (2016) Gut microbiota profiling: metabolomics based approach to unravel compounds affecting human health. Front Microbiol 7:1144

[96] Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN (2020) Heart Disease and Stroke Statistics-2020 update: a report from the American Heart Association. Circulation 141: e139–e596

[97] Wang C, Nagata S, Asahara T, Yuki N, Matsuda K, Tsuji H, Takahashi T, Nomoto K, Yamashiro Y (2015) Intestinal microbiota profiles of healthy pre-school and school-age children and effects of probiotic supplementation. Ann Nutr Metab 67:257–266

[98] Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L (2016) Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep 6:32002

[99] Wang L, Ren B, Zhang Q, Chu C, Zhao Z, Wu J, Zhao W, Liu Z, Liu X (2020) Methionine restriction alleviates high-fat diet-induced obesity: involvement of diurnal metabolism of lipids and bile acids. Biochim Biophys Acta 1866:165908

[100] Whang A, Nagpal R, Yadav H (2019) Bi-directional drug-microbiome interactions of anti-diabetics. EbioMedicine 39:591–602

[101] Whitman WB, Coleman DC, Wiebe WJ (1998) Prokaryotes: the unseen majority. Proc Natl Acad Sci USA 95:6578–6583

[102] Worthmann A, John C, Ruhlemann MC, Baguhl M, Heinsen FA, Schaltenberg N, Heine M, Schlein C, Evangelakos I, Mineo C (2017) Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. Nat Med 23:839–849

[103] Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334:105–108

[104] Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, Stahlaman M, Olsson LM, Serino M, Planas-Felix M (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:850–858

[105] Xie C, Jiang C, Shi J, Gao X, Sun D, Sun L, Wang T, Takahashi S, Anitha M, Krausz KW (2017) An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice. Diabetes 66:613–626

[106] Yao CK, Muir JG, Gibson PR (2016) Review article: insights into colonic protein fermentation, its modulation and potential health implications. Aliment Pharmacol Ther 43:181–196

[107] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver diseasemeta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84

[108] Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M (2015) Personalized nutrition by prediction of glycemic responses. Cell 163:1079–1094

[109] Zelante T, Iannitti Rossana G, Cunha C, De Luca A, Giovannini G, Pieraccini G, Zecchi R, D’Angelo C, Massi-Benedetti C, Fallarino F (2013) Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39:372–385

[110] Zhang Q, Li Y, Chen L (2015) Effect of berberine in treating type 2 diabetes mellitus and complications and its relevant mechanisms. China J Chin Mater Med 40:1660–1665

[111] Zhang L, Xie C, Nichols RG, Chan SH, Jiang C, Hao R, Smith PB, Cai J, Simons MN, Hatzakis E (2016) Farnesoid X receptor signaling shapes the gut microbiota and controls hepatic lipid metabolism. mSystems 1:e00070

[112] Zhang W, Xu JH, Yu T, Chen QK (2019a) Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. Biomed Pharmacother 118:109131

[113] Zhang X, Zhang Y, Wang P, Zhang SY, Dong Y, Zeng G, Yan Y, Sun L, Wu Q, Liu H (2019b) Adipocyte hypoxia-inducible factor 2alpha suppresses atherosclerosis by promoting adipose ceramide catabolism. Cell Metab 30(937–951):e935

[114] Zhang Z, Zhou H, Zhou X, Sun J, Liang X, Lv Y, Bai L, Zhang J, Gong P, Liu T (2020) Lactobacillus casei YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway. Br J Nutr. https://doi.org/10.1017/S0007114520003001

[115] Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14:88–98

[116] Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57:601–609

RIGHTS & PERMISSIONS

2020 The Author(s)